Основная статистика
| CIK | 1800315 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Galecto, Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39655 GALECTO, INC. |
|
| June 20, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2025 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39655 GALECTO, INC. |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| March 19, 2025 |
Retention Agreement between Galecto Biotech ApS and Hans Schambye, dated October 7, 2024. Exhibit 10.9 Retention Agreement GALECTO BIOTECH ApS and Hans Thalsgård Schambye GALECTO BIOTECH ApS CVR no. 34878366 Ole Maaløes Vej 3 2200 København N (the "Company") and Hans Thalsgård Schambye [Address] (the "CEO") (each a "Party" and collectively referred to as the "Parties") have today entered into this Retention Agreement (the "Retention Agreement") relating to the service agreement between |
|
| March 19, 2025 |
Certificate of Amendment to Amended and Restated By-laws of the Registrant. EXHIBIT 3.5 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED BY-LAWS OF GALECTO, INC. This Certificate of Amendment (this “Amendment”) to the Amended and Restated By-laws (the “By-laws”) of Galecto, Inc., a Delaware corporation (the “Company”), is effective as of March 13, 2025 and is made pursuant to Article VI, Section 9(a) of the By-laws. 1. Section 5 of Article I of the By-laws is hereby a |
|
| March 19, 2025 |
License Agreement between Bridge Medicines LLC and Rockefeller University, dated February 3, 2020. Exhibit 10.15 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. BRIDGE MEDICINES LICENSE AGREEMENT This BRIDGE MEDICINES LICENSE AGREEMENT (“Agreement”), dated as of January 31, 2020 (the “Effective Date”), is by and between |
|
| March 19, 2025 |
Statement of Company Policy on Insider Trading and Disclosure. EXHIBIT 19.1 GALECTO, INC. STATEMENT OF COMPANY POLICY ON INSIDER TRADING AND DISCLOSURE This memorandum sets forth the policy of Galecto, Inc. and its subsidiaries (collectively, the “Company”) regarding trading in the Company’s securities and the disclosure of information concerning the Company. This Statement of Company Policy on Insider Trading and Disclosure (the “Insider Trading Policy”) is |
|
| March 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ` UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39655 GALECTO, INC |
|
| March 19, 2025 |
Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK Our authorized capital stock consists of 300,000,000 shares of common stock, par value $0.00001 per share, and 10,000,000 shares of preferred stock, par value $0.00001 per share. Common Stock Holders of our common stock are entitled to one vote for each share of common stock held of record for the election of directors and on all matters submitted to a vote |
|
| March 19, 2025 |
Non-Employee Director Compensation Policy, as amended. Exhibit 10.7 Galecto, Inc. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy of Galecto, Inc. (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long- term basis, high-caliber directors who are not employees or officers of the Company or its subsidiaries. In furtherance of the purpos |
|
| March 19, 2025 |
As filed with the Securities and Exchange Commission on March 19, 2025 As filed with the Securities and Exchange Commission on March 19, 2025 Registration No. |
|
| March 19, 2025 |
Retention Compensation Agreement between the Registrant and Garrett Winslow, dated October 7, 2024. Exhibit 10.13 October 7, 2024 Garrett Winslow [Address] Re: Retention Compensation Dear Garrett: As you know, Galecto, Inc. (or its affiliate as applicable, the “Company”) greatly appreciates your efforts and hopes to continue working with you in the future. In order to encourage your continued efforts for the Company, the Company is offering you the opportunity to receive retention compensation a |
|
| March 19, 2025 |
EXHIBIT 107 Calculation of Filing Fee Table Form S-8 (Form Type) Galecto, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0.00001 par value |
|
| March 19, 2025 |
Exhibit 10.16 English Summary of a lease agreement dated November 11, 2024 (the “Lease”) by and between Galecto Biotech ApS (“Galecto”) and Symbion A/S (the “Landlord”) • Leased Property: The Lease is for the purpose of office space, with its address: Ole Maaloes Vej 3, DK-2200 Copenhagen N, Denmark. • Term: The term started December 1, 2024 and will end on November 30, 2029. • Deposit: Galecto mu |
|
| November 7, 2024 |
GLTO / Galecto, Inc. / Sunstone Life Science Ventures A/S - SC 13G Passive Investment SC 13G 1 d836936dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* GALECTO, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.00001 PER SHARE (Title of Class of Securities) 36322Q107 (CUSIP Number) DECEMBER 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropr |
|
| November 7, 2024 |
EX-99.1 2 d836936dex991.htm EX-99.1 CUSIP No. 36322Q107 13G Exhibit 99.1 Page 8 of 9 Pages Joint Filing Agreement The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing addi |
|
| November 7, 2024 |
GLTO / Galecto, Inc. / Sunstone Life Science Ventures A/S - SC 13G/A Passive Investment SC 13G/A 1 d836950dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* GALECTO, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.00001 PER SHARE (Title of Class of Securities) 36322Q206 (CUSIP Number) SEPTEMBER 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the |
|
| November 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39655 GALECTO, INC. |
|
| October 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2024 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Num |
|
| October 15, 2024 |
Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler Exhibit 99.1 Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler BOSTON, October 15, 2024 (GLOBE NEWSWIRE) - Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced the appointment of Dr. Amy Wechsler to its Board of Directors. Dr. Wechsler brings a unique combination of exp |
|
| October 7, 2024 |
Exhibit 99.2 Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines - Galecto will focus on cancer and liver disease, leveraging existing clinical stage asset GB1211 - Bolsters pipeline by obtaining global rights to BRM-1420, a novel dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of acute |
|
| October 7, 2024 |
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS On October 7, 2024, the Company completed the Closing of the Asset Purchase as further described under Item 1.01 of this Current Report on Form 8-K. The following unaudited pro forma condensed consolidated financial information is based upon the historical financial statements of the Company, adjusted to reflect the Closi |
|
| October 7, 2024 |
Exhibit 3.1 GALECTO, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A NON-VOTING CONVERTIBLE PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Galecto, Inc., a Delaware corporation (the “Corporation”), that the following resolution was duly adopted by the Board of Direc |
|
| October 7, 2024 |
Asset Purchase Agreement by and between the Registrant and Bridge Medicines LLC. Exhibit 2.1 ASSET PURCHASE AGREEMENT between Galecto, inc. as Buyer, and bridge medicines llc as Seller dated as of October 7, 2024 TABLE OF CONTENTS Page Article I DEFINITIONS 2 1.1 Definitions 2 1.2 Table of Definitions 9 Article II PURCHASE AND SALE 10 2.1 Purchase and Sale of Assets 10 2.2 Excluded Assets 11 2.3 Assumed Liabilities 12 2.4 Excluded Liabilities 12 2.5 Share Consideration 12 2.6 |
|
| October 7, 2024 |
TRANSFORMING TREATMENT of cancer and liver disease with first-in-class small molecule agents Exhibit 99. |
|
| October 7, 2024 |
Exhibit 10.1 GALECTO, INC. SUPPORT AGREEMENT THIS SUPPORT AGREEMENT (this “Agreement”), dated as of October 7, 2024 is made by and among Galecto, Inc., a Delaware corporation (“Buyer”), Bridge Medicines LLC, a Delaware limited liability company (the “Seller”), and the undersigned holder (“Stockholder”) of shares of capital stock (the “Shares”) of the Buyer. WHEREAS, concurrently with the entry int |
|
| October 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2024 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| September 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2024 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File N |
|
| September 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2024 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File N |
|
| September 5, 2024 |
Certificate of Amendment to Amended and Restated Certificate of Incorporation. Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF GALECTO, INC. Galecto, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify: 1. Pursuant to Section 242 of the DGCL, this Certificate of Amendment to the Amended and Restated Certific |
|
| September 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2024 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 29, 2024 |
GLTO / Galecto, Inc. / Otto Erik Passive Investment SC 13G/A 1 glto13Agv3.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT N0. 1) Galecto, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 36322Q107 (CUSIP Number) August 29, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| August 12, 2024 |
Employment Agreement between Galecto, Inc. and Garrett Winslow, dated April 12, 2021. Exhibit 10.1 April 12, 2021 Garrett Winslow [Address] Dear Garrett, Congratulations! Galecto, Inc. (“Galecto” or the “Company”) is very pleased to offer you employment with the following initial terms: Position Your position will be the position of General Counsel, initially reporting to Hans Schambye, effective April 26, 2021 (the “Start Date”). Your position currently is based in Boston, Massach |
|
| August 12, 2024 |
Retention Compensation Agreement between Galecto, Inc. and Garrett Winslow, dated October 19, 2023. Exhibit 10.2 October 19, 2023 Garrett Winslow [Address] Re: Retention Compensation Dear Garrett: As you know, Galecto, Inc. (or its affiliate as applicable, the “Company”) greatly appreciates your efforts and hopes to continue working with you in the future. In order to encourage your continued efforts for the Company, the Company is offering you the opportunity to receive retention compensation a |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39655 GALECTO, INC. |
|
| June 24, 2024 |
GLTO / Galecto, Inc. / Novo Holdings A/S - SC 13D/A Activist Investment SC 13D/A 1 d811382dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Galecto, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 36322Q107 (CUSIP Number) Barbara Fiorini Due Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +4 |
|
| June 21, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2024 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Number |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39655 GALECTO, INC. |
|
| April 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2024 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| March 8, 2024 |
EXHIBIT 107 Calculation of Filing Fee Table Form S-8 (Form Type) Galecto, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0.00001 par value |
|
| March 8, 2024 |
Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK Our authorized capital stock consists of 300,000,000 shares of common stock, par value $0.00001 per share, and 10,000,000 shares of preferred stock, par value $0.00001 per share, all of which shares of preferred stock are undesignated. Common Stock Holders of our common stock are entitled to one vote for each share of common stock held of record for the ele |
|
| March 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ` UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39655 GALECTO, INC |
|
| March 8, 2024 |
As filed with the Securities and Exchange Commission on March 8, 2024 As filed with the Securities and Exchange Commission on March 8, 2024 Registration No. |
|
| March 8, 2024 |
Incentive Compensation Recovery Policy. Exhibit 97 Galecto, INC. COMPENSATION RECOVERY POLICY November 16, 2023 Galecto, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Persons (as defined below) in accordance wi |
|
| March 8, 2024 |
2020 Equity Incentive Plan, and forms of award agreements thereunder. Exhibit 10.2 GALECTO, INC. 2020 EQUITY INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Galecto, Inc. 2020 Equity Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable Employees, Non-Employee Directors and Consultants of Galecto, Inc., a Delaware corporation (including any successor entity, the “Company”) and its Affiliates up |
|
| March 8, 2024 |
List of Subsidiaries of the Registrant. Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name Jurisdiction of Organization Percentage Ownership PharmAkea, Inc. Delaware 100% Galecto Securities Corporation Massachusetts 100% Galecto Biotech AB Sweden 100% Galecto Biotech ApS Denmark 100% owned by Galecto Biotech AB |
|
| December 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2023 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 6, 2023 |
Bonus Agreement between Galecto Biotech ApS and Hans Schambye, dated September 26, 2023. Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OMITTED INFORMATION HAS BEEN REPLACED BY ASTERISKS Bonus Agreement GALECTO BIOTECH ApS and Hans Thalsgård Schambye GALECTO BIOTECH ApS CVR no. 34878366 Ole Maaløes Vej 3 2200 København N (the "Company") and Hans Thalsgård |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39655 GALECTO, INC. |
|
| November 6, 2023 |
Retention Compensation Agreement between Galecto, Inc. and Jonathan Freve, dated September 26, 2023. Exhibit 10.2 September 26, 2023 Jonathan Freve [Address Omitted] Re: Retention Compensation Dear Jon: As you know, Galecto, Inc. (or its affiliate as applicable, the “Company”) greatly appreciates your efforts and hopes to continue working with you in the future. In order to encourage your continued efforts for the Company, the Company is offering you the opportunity to receive retention compensat |
|
| October 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2023 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Num |
|
| October 23, 2023 |
Exhibit 99.1 Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial Partial response seen in three of five patients with advanced non-small cell lung cancer who received GB1211 100 mg plus atezolizumab for at least three weeks Boston, MA, October 23, 2023 - Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the d |
|
| October 3, 2023 |
GLTO / Galecto Inc / Otto Erik - GALECTO13G Passive Investment 13G Template SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT N0. |
|
| October 2, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2023 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File N |
|
| September 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2023 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File N |
|
| September 26, 2023 |
Galecto Announces Plans to Explore Strategic Alternatives Exhibit 99.1 Galecto Announces Plans to Explore Strategic Alternatives Boston, MA, September 26, 2023 - Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that it has completed a review of its business, including the status of its programs, resources, and capabilities. Galecto has made the det |
|
| September 18, 2023 |
GLTO / Galecto Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 6 Activist Investment SC 13D/A 1 ss2502095sc13da.htm AMENDMENT NO. 6 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* Galecto, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 36322Q107 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Advisors Israel II Limited OrbiMed Israel GP II, L.P. OrbiMed Capital GP VII L |
|
| September 18, 2023 |
EX-99.1 2 ss2502095ex9901.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that Amendment No. 6 to Schedule 13D, dated September 12, 2023, with respect to the common stock of Galecto, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each of the unde |
|
| September 5, 2023 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Amendment No. |
|
| September 5, 2023 |
GLTO / Galecto Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 5 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Galecto, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 36322Q107 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Advisors Israel II Limited OrbiMed Israel GP II, L.P. OrbiMed Capital GP VII LLC OrbiMed Genesis GP LLC OrbiMed Capital LLC 6 |
|
| August 17, 2023 |
EX-99.1 2 ss2400578ex9901.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Amendment No. 4 to Schedule 13D, dated August 15, 2023, with respect to the common stock of Galecto, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each of the und |
|
| August 17, 2023 |
GLTO / Galecto Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 4 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Galecto, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 36322Q107 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Advisors Israel II Limited OrbiMed Israel GP II, L.P. OrbiMed Capital GP VII LLC OrbiMed Genesis GP LLC OrbiMed Capital LLC 6 |
|
| August 15, 2023 |
Exhibit 99.1 Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis Announces next steps for clinical development plan in severe liver diseases Boston, MA, August 15, 2023 - Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology, focused on the development of novel treatments f |
|
| August 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2023 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 2, 2023 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Amendment No. |
|
| August 2, 2023 |
GLTO / Galecto Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 3 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Galecto, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 36322Q107 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Advisors Israel II Limited OrbiMed Israel GP II, L.P. OrbiMed Capital GP VII LLC OrbiMed Genesis GP LLC OrbiMed Capital LLC 6 |
|
| July 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39655 GALECTO, INC. |
|
| July 17, 2023 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Amendment No. |
|
| July 17, 2023 |
GLTO / Galecto Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 2 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Galecto, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 36322Q107 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Advisors Israel II Limited OrbiMed Israel GP II, L.P. OrbiMed Capital GP VII LLC OrbiMed Genesis GP LLC OrbiMed Capital LLC 6 |
|
| June 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Number |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39655 GALECTO, INC. |
|
| April 7, 2023 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Amendment No. |
|
| April 7, 2023 |
GLTO / Galecto Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 1 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Galecto, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 36322Q107 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Advisors Israel II Limited OrbiMed Israel GP II, L.P. OrbiMed Capital GP VII LLC OrbiMed Genesis GP LLC OrbiMed Capital LLC 6 |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| March 9, 2023 |
Up to $50,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-260778 AMENDMENT NO. 2 DATED MARCH 9, 2023 to Prospectus Supplement dated November 4, 2021 (To the Prospectus Dated November 4, 2021) PROSPECTUS SUPPLEMENT Up to $50,000,000 Common Stock This Amendment No. 2 to Prospectus Supplement (this “Amendment”) amends our prospectus supplement dated November 4, 2021 (the “Prospectus Supplement”). This Am |
|
| March 9, 2023 |
As filed with the Securities and Exchange Commission on March 9, 2023 As filed with the Securities and Exchange Commission on March 9, 2023 Registration No. |
|
| March 9, 2023 |
Exhibit 4.3 DESCRIPTION OF CAPITAL STOCK Our authorized capital stock consists of 300,000,000 shares of common stock, par value $0.00001 per share, and 10,000,000 shares of preferred stock, par value $0.00001 per share, all of which shares of preferred stock are undesignated. Common Stock Holders of our common stock are entitled to one vote for each share of common stock held of record for the ele |
|
| March 9, 2023 |
EXHIBIT 107 Calculation of Filing Fee Table Form S-8 (Form Type) Galecto, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1)(2) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0.00001 par va |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39655 GALECTO, INC. |
|
| March 9, 2023 |
List of Subsidiaries of the Registrant. Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name Jurisdiction of Organization Percentage Ownership PharmAkea, Inc. Delaware 100% Galecto Securities Corporation Massachusetts 100% Galecto Biotech AB Sweden 100% Galecto Biotech ApS Denmark 100% owned by Galecto Biotech AB |
|
| March 9, 2023 |
Exhibit 99.2 GALECTO, INC. 2022 INDUCEMENT PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Galecto, Inc. 2022 Inducement Plan (the “Plan”). The purpose of the Plan is to enable Galecto, Inc. (the “Company”) to grant equity awards to induce highly-qualified prospective officers and employees who are not currently employed by the Company and its Affiliates to acc |
|
| January 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2023 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| January 6, 2023 |
EX-99.1 2 glto-ex991.htm EX-99.1 First-in-class small molecule antifibrotic and anticancer agents January 2023 Exhibit 99.1 Forward-looking statements This presentation contains forward-looking statements about Galecto, Inc.’s (“Galecto” or the “Company”) strategy, future plans, operations and prospects, including, but not limited to, statements regarding the development of Galecto’s compounds and |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39655 GALECTO, INC. |
|
| October 31, 2022 |
Exhibit 99.1 Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD’s The Liver Meeting® 2022 • Late-breaking oral and poster presentations include clinical and preclinical data related to GULLIVER-2 clinical trial • Galecto to host a webinar at 8:00 a.m. ET on Tuesday, November 8, 2022 to discuss expanded topline data and analysis |
|
| October 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2022 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Num |
|
| September 30, 2022 |
GLTO / Galecto Inc / Novo Holdings A/S - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Galecto, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 36322Q107 (CUSIP Number) Barbara Fiorini Due Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy to: B. Shayne |
|
| September 29, 2022 |
Exhibit 99.1 GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis, Validating LOXL2 as a Clinical Fibrosis Target Company to host a live conference call and webcast today, September 29, 2022, at 8:00 a.m. ET Boston, MA, September 29, 2022 - Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosi |
|
| September 29, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2022 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File N |
|
| July 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39655 GALECTO, INC. |
|
| June 17, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2022 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Number |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39655 GALECTO, INC. |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 28, 2022 |
DEF 14A 1 glto-2022-def14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as |
|
| February 18, 2022 |
Up to $50,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-260778 AMENDMENT NO. 1 DATED FEBRUARY 18, 2022 to Prospectus Supplement dated November 4, 2021 (To the Prospectus Dated November 4, 2021) PROSPECTUS SUPPLEMENT Up to $50,000,000 Common Stock This Amendment No. 1 to Prospectus Supplement (this ?Amendment?) amends our prospectus supplement dated November 4, 2021 (the ?Prospectus Supplement?). Thi |
|
| February 17, 2022 |
EXHIBIT 107 Calculation of Filing Fee Table Form S-8 (Form Type) Galecto, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1)(2) Proposed Maximum Offering Price Per Share(3) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0.00001 par |
|
| February 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 c FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39655 GALECTO, INC |
|
| February 17, 2022 |
Exhibit 4.3 DESCRIPTION OF CAPITAL STOCK Our authorized capital stock consists of 300,000,000 shares of common stock, par value $0.00001 per share, and 10,000,000 shares of preferred stock, par value $0.00001 per share, all of which shares of preferred stock are undesignated. Common Stock Holders of our common stock are entitled to one vote for each share of common stock held of record for the ele |
|
| February 17, 2022 |
As filed with the Securities and Exchange Commission on February 17, 2022 As filed with the Securities and Exchange Commission on February 17, 2022 Registration No. |
|
| February 17, 2022 |
List of Subsidiaries of the Registrant. Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name Jurisdiction of Organization Percentage Ownership PharmAkea, Inc. Delaware 100% Galecto Securities Corporation Massachusetts 100% Galecto Biotech AB Sweden 100% Galecto Biotech ApS Denmark 100% owned by Galecto Biotech AB |
|
| February 14, 2022 |
GLTO / Galecto Inc / Cormorant Asset Management, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Galecto, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 36322Q107 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 11, 2022 |
GLTO / Galecto Inc / HBM Healthcare Investments (Cayman) Ltd. - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Galecto, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 36322Q107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| February 10, 2022 |
EXHIBIT A JOINT FILING AGREEMENT Soleus Private Equity GP I, LLC, a Delaware limited liability company, Soleus Private Equity Fund I, L. |
|
| February 10, 2022 |
GLTO / Galecto Inc / Soleus Private Equity Fund I, L.P. - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* GALECTO, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 36322Q107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 9, 2022 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2022 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Num |
|
| February 9, 2022 |
Non-Employee Director Compensation Policy, as amended Exhibit 10.1 Galecto, Inc. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy of Galecto, Inc. (the ?Company?), is to provide a total compensation package that enables the Company to attract and retain, on a long- term basis, high-caliber directors who are not employees or officers of the Company or its subsidiaries. In furtherance of the purpos |
|
| January 27, 2022 |
Exhibit 99.1 Galecto Publishes Results Showing Safety and Efficacy of the GB0139 Inhaled Galectin-3 Inhibitor in Hospitalized COVID-19 Patients on Standard of Care Results Support Favorable Safety and Tolerability Profile and Target Engagement of GB0139 and Potential for GB0139 in Severe Lung Disease Company Provides Update on GALACTIC-1 Trial Boston, MA, January 27, 2022 - Galecto, Inc. (NASDAQ: |
|
| January 27, 2022 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2022 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Num |
|
| January 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2022 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| January 5, 2022 |
First-in-class small-molecule anti-fibrotic and anti-cancer agents January 2022 Exhibit 99. |
|
| November 10, 2021 |
GALECTO, INC. Ole Maaloes Vej 3 DK-2200 Copenhagen N CORRESP 1 filename1.htm GALECTO, INC. Ole Maaloes Vej 3 DK-2200 Copenhagen N Denmark November 10, 2021 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Galecto, Inc.: Registration Statement on Form S-3 filed November 4, 2021 (File No. 333-260778) Ladies and Gentlemen: Pursuant to Rule 461 under the |
|
| November 4, 2021 |
Form of Subordinated Indenture Exhibit 4.4 GALECTO, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?] Subordinated Debt Securities TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Certificate 8 Secti |
|
| November 4, 2021 |
Sales Agreement, dated November 4, 2021, by and between the Registrant and Jefferies LLC Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM November 4, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Galecto, Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the ?Agent?), shares of the Company?s common stock, pa |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39655 GALECTO, INC. |
|
| November 4, 2021 |
Exhibit 4.3 GALECTO, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?] Senior Debt Securities TABLE OF CONTENTS Page Article 1 DEFINITIONS 1 Section 1.01Definitions of Terms1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01Designation and Terms of Securities5 Section 2.02Form of Securities and Trustee?s Certificate8 Section 2.03Denom |
|
| November 4, 2021 |
As filed with the Securities and Exchange Commission on November 4, 2021 As filed with the Securities and Exchange Commission on November 4, 2021 Registration No. |
|
| August 5, 2021 |
Exhibit 10.1 English Summary of a lease agreement dated April 15, 2021 (the ?Lease?) by and between Galecto Biotech ApS (?Galecto?) and Symbion A/S (the ?Landlord?) ? Leased Property: The Lease is for the purpose of office space, with its address: Ole Maaloes Vej 3, DK-2200 Copenhagen N, Denmark. ? Term: The term started at May 1, 2021 and will end on January 31, 2025. ? Deposit: Galecto must prov |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39655 GALECTO, INC. |
|
| July 6, 2021 |
Executive Separation Benefits Plan Exhibit 10.1 Galecto, Inc. Executive Separation Benefits Plan 1. Establishment of Plan. Galecto, Inc., a Delaware corporation, is establishing this unfunded separation benefits plan (the ?Plan?) that is intended to be a welfare benefit plan within the meaning of Section 3(1) of ERISA. The Plan is in effect for Covered Employees of the Company and its Applicable Subsidiaries who experience a Covere |
|
| July 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2021 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 28, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2021 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39655 GALECTO, INC. |
|
| April 14, 2021 |
DEFA14A 1 glto-defa14a20210414.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| April 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 29, 2021 |
As filed with the Securities and Exchange Commission on March 29, 2021 Registration No. |
|
| March 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39655 GALECTO, INC. |
|
| March 29, 2021 |
List of Subsidiaries of the Registrant. Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name Jurisdiction of Organization Percentage Ownership PharmAkea, Inc. California 100% Galecto Securities Corporation Massachusetts 100% Galecto Biotech AB Sweden 100% Galecto Biotech ApS Denmark 100% owned by Galecto Biotech AB |
|
| March 29, 2021 |
2020 Equity Incentive Plan, and forms of award agreements thereunder. Exhibit 10.2 GALECTO, INC. 2020 EQUITY INCENTIVE PLAN (1) GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Galecto, Inc. 2020 Equity Incentive Plan (the ?Plan?). The purpose of the Plan is to encourage and enable Employees, Non-Employee Directors and Consultants of Galecto, Inc., a Delaware corporation (including any successor entity, the ?Company?) and its Affiliates upon whos |
|
| March 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2021 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| March 15, 2021 |
Exhibit 99.1 Galecto Announces Outcome of Data Safety Monitoring Board Interim Review of Phase 2b GALACTIC-1 Study of GB0139 for Idiopathic Pulmonary Fibrosis: DSMB Recommends Study to Continue with Modifications Galecto expects to continue dosing patients in the 3 mg arm, whereas the 10 mg arm and combinations with nintedanib or pirfenidone will be discontinued at the recommendation of the DSMB B |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Galecto, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 36322Q107 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 12, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* GALECTO, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 36322Q107 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Galecto, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 36322Q107 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| January 8, 2021 |
Galecto Appoints Anne Prener to its Board of Directors Exhibit 99.1 Galecto Appoints Anne Prener to its Board of Directors Boston, Jan. 8, 2021 (GLOBE NEWSWIRE) – Galecto, Inc., (NASDAQ: GLTO) a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced the appointment of Dr. Anne Prener to its Board of Directors. “We warmly welcome Anne to our Board. She will be a tremendous asset with |
|
| January 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2021 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| January 5, 2021 |
First-in-class small-molecule anti-fibrotic and anti-cancer agents January 2021 First-in-class small-molecule anti-fibrotic and anti-cancer agents January 2021 Forward-looking statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. |
|
| January 5, 2021 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2021 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| December 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39655 GALECTO, INC. |
|
| November 23, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2020 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission Fil |
|
| November 23, 2020 |
Non-Employee Director Compensation Policy EX-10.1 Exhibit 10.1 GALECTO, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy of Galecto, Inc. (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long- term basis, high-caliber directors who are not employees or officers of the Company or its subsidiaries. In furtherance of th |
|
| November 23, 2020 |
Galecto Appoints Experienced Healthcare Executive Jayson Dallas to Board of Directors EX-99.1 Exhibit 99.1 Galecto Appoints Experienced Healthcare Executive Jayson Dallas to Board of Directors • Has extensive experience in pharma and biotech in U.S., Europe and globally • Galecto completed U.S. initial public offering and plans to initiate three Phase 2 trials in the coming months Boston, MA/Copenhagen, Denmark, November 23, 2020 - Galecto, Inc. (NASDAQ: GLTO), a clinical stage b |
|
| November 12, 2020 |
GLTO / Galecto, Inc. / Cormorant Asset Management, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Galecto, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 36322Q107 (CUSIP Number) November 2, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| November 12, 2020 |
Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of November 12, 2020, is by and among Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare Fund II, LP, Cormorant Private Healthcare GP II, LLC, Cormorant Private Healthcare Fund III, LP, Cormorant Private Healthcare GP III, LLC, Cormorant Asset Management, LP and Bih |
|
| November 12, 2020 |
GLTO / Galecto, Inc. / Soleus Private Equity Fund I, L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* GALECTO, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 36322Q107 (CUSIP Number) November 2, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| November 6, 2020 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated November 6, 2020, with respect to the ordinary shares of Galecto, Inc. |
|
| November 6, 2020 |
GLTO / Galecto, Inc. / ORBIMED ADVISORS LLC - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Galecto, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 36322Q107 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VII LLC OrbiMed Advisors Israel II Limited OrbiMed Israel GP II, L.P. OrbiMed Genesis GP LLC OrbiMed Capital LLC 601 Lexington Avenue |
|
| November 5, 2020 |
GLTO / Galecto, Inc. / Novo Holdings A/S - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* GALECTO, INC. (Name of Issuer) Common Stock, par value $ 0.00001 per share (Title of Class of Securities) 36322Q107 (CUSIP Number) Peter Haahr Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy to: B. Shayne Kennedy, |
|
| November 5, 2020 |
Form of lock-up from directors, officers or other stockholders October , 2020 EX-99.1 Exhibit 99.1 Form of lock-up from directors, officers or other stockholders October , 2020 BofA Securities, Inc., SVB Leerink LLC, Credit Suisse Securities (USA) LLC as Representatives of the several Underwriters to be named in the within-mentioned Underwriting Agreement c/o BofA Securities, Inc. One Bryant Park New York, New York 10036 c/o SVB Leerink LLC 1301 Avenue of the Americas, 12th |
|
| November 4, 2020 |
Amended and Restated By-laws of Galecto, Inc. EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BY-LAWS OF GALECTO, INC. (the “Corporation”) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these By-laws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, date and place may su |
|
| November 4, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2020 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File |
|
| November 4, 2020 |
S-8 As filed with the Securities and Exchange Commission on November 4, 2020 Registration No. |
|
| November 4, 2020 |
Amended and Restated Certificate of Incorporation of Galecto, Inc. EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF GALECTO, INC. Galecto, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The name of the Corporation is Galecto, Inc. The date of the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware was |
|
| October 30, 2020 |
424B4 Table of Contents Filed pursuant to Rule 424(b)(4) Registration No. 333-249369 PROSPECTUS 5,666,667 Shares Common Stock This is Galecto, Inc.’s initial public offering. We are selling 5,666,667 shares of our common stock. The initial public offering price is $15.00 per share. Currently, no public market exists for our common stock. Our common stock has been approved for listing on The Nasdaq |
|
| October 26, 2020 |
CORRESP Goodwin Procter LLP 620 8th Avenue New York, NY 10018 goodwinlaw.com +1 212 813 8800 October 26, 2020 VIA EDGAR Office of Life Sciences Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Donald Field Susan Block Kristin Lochhead Kate Tillan Re: Galecto, Inc. Erez Chimovits, Søren Lemonius, Chandra Leo and Karen Wagner Res |
|
| October 23, 2020 |
CORRESP VIA EDGAR October 23, 2020 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Donald Field Susan Block Kristin Lochhead Kate Tillan Re: Galecto, Inc. Acceleration Request for Registration Statement on Form S-1 File No. 333-249369 Requested Date: October 27, 2020 Requested Time: 4:00 p.m. Eastern St |
|
| October 23, 2020 |
Registration Statement on Form 8-A Form 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 37-1957007 (State of incorporation or organization) (I.R.S. Employer Identification No.) Ole Maalos Vej 3 D |
|
| October 23, 2020 |
CORRESP October 23, 2020 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Donald Field Susan Block Kristin Lochhead Kate Tillan Re: Galecto, Inc. Registration Statement on Form S-1, as amended (Registration No. 333-249369) Dear Mr. Field: In connection with the above-referenced Registration Statement, as |
|
| October 22, 2020 |
EX-10.14 Exhibit 10.14 English Summary of a lease agreement dated May 4, 2020 (the “Lease”) by and between Galecto Biotech ApS (“Galecto”) and COBIS A/S (the “Landlord”) • Leased Property: the Lease is for the purpose of office space, with its address: Ole Maaloes Vej 3, DK-2200 Copenhagen N, Denmark. • Term: The term started at June 1, 2020 and will end on October 31, 2021 • Deposit: Galecto must |
|
| October 22, 2020 |
Senior Executive Cash Incentive Bonus Plan. EX-10.3 Exhibit 10.3 GALECTO, INC. SENIOR EXECUTIVE CASH INCENTIVE BONUS PLAN 1. Purpose This Senior Executive Cash Incentive Bonus Plan (the “Incentive Plan”) is intended to provide an incentive for superior work and to motivate eligible executives of Galecto, Inc. (the “Company”) and its subsidiaries toward even higher achievement and business results, to tie their goals and interests to those o |
|
| October 22, 2020 |
S-1/A Table of Contents As filed with the Securities and Exchange Commission on October 22, 2020 Registration No. |
|
| October 22, 2020 |
EX-4.2 Exhibit 4.2 FINAL AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT TABLE OF CONTENTS Page 1. Definitions 1 2. Registration Rights 5 2.1 Demand Registration 5 2.2 Company Registration 7 2.3 Underwriting Requirements 7 2.4 Obligations of the Company 8 2.5 Furnish Information 9 2.6 Expenses of Registration 10 2.7 Delay of Registration 10 2.8 Indemnification 10 2.9 Reports Under Exchange Act 12 |
|
| October 22, 2020 |
EX-3.3 Exhibit 3.3 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF GALECTO, INC. Galecto, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The name of the Corporation is Galecto, Inc. The date of the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware was |
|
| October 22, 2020 |
Form of Indemnification Agreement between the Registrant and each of its executive officers. EX-10.4 Exhibit 10.4 GALECTO, INC. [FORM OF] OFFICER INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made as of [Date] by and between Galecto, Inc., a Delaware corporation (the “Company”), and [Officer Name] (“Indemnitee”). 1 RECITALS WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, to serve the Company; |
|
| October 22, 2020 |
EX-10.2 Exhibit 10.2 GALECTO, INC. 2020 EQUITY INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Galecto, Inc. 2020 Equity Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable Employees, Non-Employee Directors and Consultants of Galecto, Inc., a Delaware corporation (including any successor entity, the “Company”) and its Affil |
|
| October 22, 2020 |
Specimen Common Stock Certificate. EX-4.1 Exhibit 4.1 ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# Exhibit 4.1 COMMON STOCK PAR VALUE $0.00001 COMMON STOCK Certificate Number ZQ00000000 GALECTO, INC. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE Shares THIS CERTIFIES THAT SEE REVERSE FOR CERTAIN DEFINITIONS is the owner of THIS CERTIFICATE IS TRANSFERABLE IN CITIES DESIGNATED BY THE TRANSFER AGENT, AVAILABLE ONLINE AT |
|
| October 22, 2020 |
Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Registrant. EX-3.2 Exhibit 3.2 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF GALECTO, INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) Galecto, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that: 1. The name |
|
| October 22, 2020 |
EX-3.5 Exhibit 3.5 AMENDED AND RESTATED BY-LAWS OF GALECTO, INC. (the “Corporation”) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these By-laws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, date and place may su |
|
| October 22, 2020 |
Form of Underwriting Agreement. EX-1.1 Exhibit 1.1 GALECTO, INC. (a Delaware corporation) [•] Shares of Common Stock UNDERWRITING AGREEMENT Dated: [•], 2020 GALECTO, INC. (a Delaware corporation) [•] Shares of Common Stock UNDERWRITING AGREEMENT [•], 2020 BofA Securities, Inc. SVB Leerink LLC, Credit Suisse Securities (USA) LLC as Representatives of the several Underwriters c/o BofA Securities, Inc. One Bryant Park New York, New |
|
| October 22, 2020 |
Non-Employee Director Compensation Policy. EX-10.6 Exhibit 10.6 GALECTO, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy of Galecto, Inc. (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or its subsidiaries. In furtherance of the |
|
| October 22, 2020 |
Employment Agreement between Galecto, Inc. and Jonathan Freve, dated March 11, 2020. EX-10.12 Exhibit 10.12 Jonathan P. Freve Dear Jon: On behalf of Galecto, Inc. a Delaware corporation (the “Company”), I am pleased to set forth below the terms of your employment with the Company, which will take effect as of April 20, 2020 (or a mutually agreed upon alternative date): 1. You will be employed to serve on a full-time basis as Chief Financial Officer of the Company. As Chief Financi |
|
| October 22, 2020 |
2020 Stock Option and Grant Plan. EX-10.1 Exhibit 10.1 GALECTO, INC. 2020 STOCK OPTION AND GRANT PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Galecto, Inc. 2020 Stock Option and Grant Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, directors, Consultants and other key persons of Galecto, Inc., a Delaware corporation (including any successor enti |
|
| October 22, 2020 |
Form of Indemnification Agreement between the Registrant and each of its directors. EX-10.5 Exhibit 10.5 GALECTO, INC. [FORM OF] DIRECTOR INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made as of [Date] by and between Galecto, Inc, a Delaware corporation (the “Company”), and [Director Name] (“Indemnitee”). RECITALS WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, to serve the Company; W |
|
| October 20, 2020 |
CORRESP October 20, 2020 Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| October 13, 2020 |
CORRESP FOIA CONFIDENTIAL TREATMENT REQUEST The entity requesting confidential treatment is: Galecto, Inc. |
|
| October 7, 2020 |
List of Subsidiaries of the Registrant. EX-21.1 Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Incorporation PharmAkea, Inc. Delaware Galecto Biotech AB Sweden Galecto Biotech ApS Denmark |
|
| October 7, 2020 |
CORRESP October 7, 2020 Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| October 7, 2020 |
EX-4.2 Exhibit 4.2 FINAL AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT TABLE OF CONTENTS Page 1. Definitions 1 2. Registration Rights 5 2.1 Demand Registration 5 2.2 Company Registration 7 2.3 Underwriting Requirements 7 2.4 Obligations of the Company 8 2.5 Furnish Information 9 2.6 Expenses of Registration 10 2.7 Delay of Registration 10 2.8 Indemnification 10 2.9 Reports Under Exchange Act 12 |
|
| October 7, 2020 |
Bylaws of the Registrant, as currently in effect. EX-3.4 Exhibit 3.4 GALECTO, INC. BYLAWS Adopted December 4, 2019 ARTICLE I- STOCKHOLDERS Section 1 Annual Meeting. An annual meeting of the stockholders, for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting, shall be held at such place, on such date, and at such time as the Board of Directors shall |
|
| October 7, 2020 |
Amendment to Employment Agreement between Galecto, Inc. and Jonathan Freve, dated March 14, 2020. EX-10.13 Exhibit 10.13 AMENDMENT TO EMPLOYMENT AGREEMENT This amendment to the Employment Agreement of Jonathan Freve is made and entered into between Galecto, Inc. (the “Company”), and Jonathan Freve, (the “Employee” or “You”), (together, the “Parties”). WHEREAS, the Company and the Employee entered into an Employment Agreement dated as of March 11, 2010 (the “Employment Agreement”) and WHEREAS, |
|
| October 7, 2020 |
Employment Agreement between Galecto, Inc. and Jonathan Freve, dated March 11, 2020. EX-10.12 Exhibit 10.12 Jonathan P. Freve Dear Jon: On behalf of Galecto, Inc. a Delaware corporation (the “Company”), I am pleased to set forth below the terms of your employment with the Company, which will take effect as of April 20, 2020 (or a mutually agreed upon alternative date): 1. You will be employed to serve on a full-time basis as Chief Financial Officer of the Company. As Chief Financi |
|
| October 7, 2020 |
Service Agreement between Galecto Biotech ApS and Hans Schambye, dated April 23, 2013. EX-10.7 Exhibit 10.7 SERVICE AGREEMENT March 2013 Galecto Biotech ApS and Hans Schambye Galecto Biotech ApS CVR no. 34 87 83 66 Ole Maaloes Vej 3 2200 Copenhagen N (the “Company”) and Hans Schambye (the “CEO”) (jointly, the “Parties”) have today entered into this service agreement (the “Agreement”). 1. Commencement of service 1.1 The CEO serves as chief executive officer of the Company and effecti |
|
| October 7, 2020 |
Power of Attorney (included on signature page to this registration statement). Form S-1 Table of Contents As filed with the Securities and Exchange Commission on October 7, 2020 Registration No. |
|
| October 7, 2020 |
EX-10.9 Exhibit 10.9 Copenhagen - August 2017 Addendum to the Employment Contract Galecto Biotech ApS CVR no. 34 87 83 66 Ole Maal0es Vej 3 DK-2200 Copenhagen (the “Company’’) and Anders H. Pedersen *** *** (the “Employee’’) (each a “Party” and jointly the “Parties”) have today entered into this addendum (the “Addendum”) to the employment contract dated 23 January 2013 (the “Employment Contract”). |
|
| October 7, 2020 |
EX-10.8 Exhibit 10.8 EMPLOYMENT CONTRACT December 2012 GALECTO BIOTECH ApS and Anders H. Pedersen GALECTO BIOTECH ApS 1 CVR-nr. 34878366 c/o Cobis A/S Ole Maaloes Vej 3 2200 Kobenhavn N (the “Company”) and Anders H. Pedersen (the “Employee”) (jointly, the “Parties”) have today entered into this employment contract (the “Contract”). 1. Date of employment 1.1 The Employee will be employed with the C |
|
| October 7, 2020 |
Employment Contract between Galecto Biotech ApS and Bertil E. Lindmark, dated November 28, 2019. EX-10.10 Exhibit 10.10 Employment Contract Galecto Biotech ApS and Bertil E. Lindmark Galecto Biotech ApS CVR no. 34878366 c/o Cobis A/S Ole Maaloes Vej 3 2200 Kobenhavn N Denmark (the “Company”) and Bertil E. Lindmark (the “Employee”) (each a “Party” and collectively the “Parties”) have today entered into this employment contract (the “Employment Contract”). 1. Date of Employment 1.1 The Employee |
|
| October 7, 2020 |
Amended and Restated Certificate of Incorporation of the Registrant as currently in effect. EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF GALECTO, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Galecto, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “DGCL”), DOES HEREBY CERTIFY: 1. That the name of this corporation is Ga |
|
| October 7, 2020 |
EX-10.11 Exhibit 10.11 Addendum to Employment Contract Galecto Biotech ApS CVR no. 34878366 c/o Cobis A/S Ole Maaloes Vej 3 2200 Kobenhavn N Denmark (the “Company”) and Bertil E. Lindmark (the “Employee”) (each a “Party”) have today entered into this addendum to the employment contract of 28 November 2019. 1. Date of Employment 1.1 The Employee will be employed with the Company from 1 February 202 |
|
| September 2, 2020 |
DRS Table of Contents As confidentially submitted to the Securities and Exchange Commission on September 2, 2020. |
